Peptide imaging agent developer Diatech of Londonderry, NH, hasreceived a broad patent from the U.S. Patent and Trademark Officecovering its core technology of attaching peptides to technetium-99mradioisotopes. The patent covers Diatech's work on several
Peptide imaging agent developer Diatech of Londonderry, NH, hasreceived a broad patent from the U.S. Patent and Trademark Officecovering its core technology of attaching peptides to technetium-99mradioisotopes. The patent covers Diatech's work on several products,including agents for imaging disease states such as deep veinthrombosis, pulmonary emboli, tumors and atherosclerotic plaque.Diatech said the patent puts it in a strong proprietary positionas it works to commercialize the agents.
The company also announced this month that it has receiveda $100,000 grant from the Heart and Lung Blood Institute divisionof the National Institutes of Health to research a potential newtherapeutic agent for the treatment of blood clots.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.